Literature DB >> 31669156

Lorlatinib: a new treatment option for ROS1-positive lung cancer.

Michaël Duruisseaux1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31669156     DOI： 10.1016/S1470-2045(19)30716-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Role of Long Noncoding RNAs in Smoking-Induced Lung Cancer: An In Silico Study.

Authors:  Lei Ge; Shishun Zhao; Jianguo Sun; Jianhua Cheng; Shaokun Wang
Journal:  Comput Math Methods Med       Date:  2022-04-30       Impact factor: 2.809

2.  Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: A case report.

Authors:  Jinjing Wang; Shuai Luo; Yao Li; Hong Zheng
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.